Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Abstract Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far hampered broader clinical application, es...
Main Authors: | Johannes P. W. Heidbuechel, Christine E. Engeland |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-021-01075-5 |
Similar Items
-
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
by: Amanda Rosewell Shaw, et al.
Published: (2018-09-01) -
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
by: Tao Shi, et al.
Published: (2020-04-01) -
The landscape of bispecific T cell engager in cancer treatment
by: Shujie Zhou, et al.
Published: (2021-05-01) -
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
by: Jana de Sostoa, et al.
Published: (2019-01-01) -
New developments in immunotherapy for lymphoma
by: Benjamin Heyman, et al.
Published: (2018-09-01)